

Breast MRI


Dr M Telesca
Consultant Radiologist
Worcestershire Acute Hospitals NHS Trust



2010






Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group

Francesco Sardanelli ^{a,*}, Carla Boetes ^b, Bettina Borisch ^c, Thomas Decker ^d, Massimo Federico ^e, Fiona J. Gilbert ^f, Thomas Helbich ^g, Sylvia H. Heywang-Köbrunner ^h, Werner A. Kaiser ⁱ, Michael J. Kerin ^j, Robert E. Mansel ^k, Lorenza Marotti ^l, Laura Martincich ^m, Louis Mauriac ⁿ, Hanne Meijers-Heijboer ^o, Roberto Orecchia ^p, Pietro Panizza ^q, Antonio Ponti ^r, Arnie D. Purushotham ^s, Peter Regitnig ^t, Marco Rosselli Del Turco ^l, Fabienne Thibault ^u, Robin Wilson ^v



- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.

Staging (preop MRI)	Limited¹
Screening high-risk women	YES
Evaluation of response to NAC	YES
Augmentation or reconstruction <i>(suspected implant rupture)</i>	YES
Occult primary breast cancer	YES
Suspected local recurrence	YES
Equivocal findings at mammo/US	Limited²



¹ ILC, high-risk, Mx/US size discrepancy, PBI

² When CNB/VAB cannot be performed

Recommended

- Invasive lobular carcinoma
- High risk patients
- Discordance in tumour size assessment (>1cm)
- ?Eligible for PBI

Evidence needed – creeping practice

- Dense breasts
- Involved/close margins
- Unilateral, unifocal pure DCIS
(?synchronous invasive)
- Paget's disease

Preoperative Magnetic Resonance Imaging in Breast Cancer

Meta-Analysis of Surgical Outcomes

Nehmat Houssami, MBBS, PhD,* Robin Turner, PhD,* and Monica Morrow, MD†

Background and Objective: The role of breast magnetic resonance imaging (MRI) in women newly diagnosed with breast cancer (BC) is controversial. This meta-analysis examines the effect of preoperative MRI compared with standard preoperative assessment on surgical outcomes, focusing on studies that used a controlled design.

Methods: Using random-effects logistic meta-regression modeling, we estimated the proportion of women with each outcome in the MRI versus no-MRI groups, and calculated the odds ratio (OR) and adjusted OR (adjusted for study-level median age, and, where appropriate, for temporal effect) for each model.

Results: There were 9 eligible studies (2 randomized trials; 7 comparative cohorts). Outcomes in 3112 patients with BC (any histological tumor type) for MRI versus no-MRI (referent) were as follows: initial mastectomy 16.4% versus 8.1% [OR, 2.22 ($P < 0.001$); adjusted OR, 3.06 ($P < 0.001$)]; re-excision after initial breast conservation 11.6% versus 11.4% [OR, 1.02 ($P = 0.87$); adjusted OR, 0.95 ($P = 0.71$)]; overall mastectomy 25.5% versus 18.2% [OR, 1.54 ($P < 0.001$); adjusted OR, 1.51 ($P < 0.001$)]. In 766 patients with invasive lobular cancer (ILC), outcomes were as follows: initial mastectomy 31.1% versus 24.9% [OR, 1.36 ($P = 0.056$); adjusted OR, 2.12 ($P = 0.008$)]; re-excision after initial breast conservation 10.9% versus 18.0% [OR, 0.56 ($P = 0.031$); adjusted OR, 0.56 ($P = 0.09$)]; overall mastectomy 43.0% versus 40.2% [OR, 1.12 ($P = 0.45$); adjusted OR, 1.64 ($P = 0.034$)].

Conclusions: Our summary of the evidence showed that MRI significantly increased mastectomy rates and suggests an unfavorable harm-benefit ratio for routine use of preoperative MRI in BC. We found weak evidence that MRI reduced re-excision surgery in patients with ILC—although this was at the expense of increased mastectomies—and overall patient benefit from MRI in ILC is not clear from this study.


9 studies (2 randomized, 7 comparative) all using a controlled study design

3112 patients with BC





MRI impact on short term surgical outcomes only

- Contralateral preop-MRI depicted 25 (1.4%) additional cancers

Suspected right lower lobe
carcinoid with obstructive
atelectasis



Two avid nodules in the R
breast. Patient referred for triple
assessment in the breast clinic








5. 1: T1 Dyn Gad

May-2018
29:07
n Nr. 5, 2
FEW
6ms
Angle 15°
3:09

Zoom 95



Subtracted - 6, 1: T1 Dyn Gad





DI: 200
L: 144
W: 275



L4P9.4CE

Copyright 2008 Philips

A
R F



L breast : grade 1 invasive ductal carcinoma;B5b






43 yo lady

**firm palpable lump at
3 o'clock in the right
breast.**



**US guide core:
G3 IDC**



Multicentric disease: mastectomy

INVASIVE LOBULAR CARCINOMA

MRI 83-100%
Mx 57-81%
US 68-87%

MRI sensitivity for detecting ILC is superior to MX and US

*Brem RF, Am J Roentgenol 2009;192:379-83.
Mann RM. Breast Cancer Res Treat 2008;107:1-14.*

Breast Cancer Res Treat (2010) 119:415-422
DOI 10.1007/s10549-009-0616-6

CLINICAL TRIAL

The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast

R. M. Mann · C. E. Loo ·
T. Wobbes · P. Bult · J. O. Barentsz ·
K. G. A. Gilhuijs · C. Boetes

Table 3 Rate of re-excisions and mastectomies in the entire study population

	MR- (N = 168)	MR+ (N = 99)	P value
Re-excisions	25 (15)	5 (5)	0.014
Initial mastectomies	78 (46)	44 (45)	0.753
Final mastectomies	99 (59)	48 (48)	0.098

Numbers between parenthesis represent percentages



Table 4 Results in the subset of patients that initially underwent BCS



	MRi-	MRi+	P value
N	90	55	
Mean tumor size (cm)	2.1 ± 1.4	2.0 ± 1.4	0.724
Multifocal	37 (41)	19 (34)	0.431
Re-excisions	24 (27)	5 (9)	0.010
Final mastectomies	21 (23)	4 (7)	0.013

Numbers between parenthesis represent percentages

73 yo lady



**screen detected ILC
L breast**









Subtracted - 6.1: DYN eTHRIVE | Table Viewer | Anatomical Viewer

Graph Viewer | Anatomical Viewer



C



Annual MRI as screening test to selected population:

- High risk = >20 – 30% lifetime risk
- Genetic/family history
- Previous high dose RT
- Prior to risk reducing mastectomy – within 3/12

SCREENING FOR HIGH RISK PATIENTS

HIBCRIT-1

Modality	Sensitivity %	Specificity %	PPV2 %	NPV %
CBE	17.6	99.4	60.0	96.1
Mammography	50.0	99.1	73.5	97.6
US	52.0	99.2	76.5	97.7
MRI	91.3 *	97.4	61.8	99.6 *
Mam + US	62.5	98.4	65.2	98.2
MRI + Mammo	93.2	97.0	58.6	99.7
MRI + US	93.3	97.1	60.0	99.7

18 centers
501 women
1592 rounds


*** Stat significant**

Sensitivity for pT1a-b

Mammo & US 10/20 50%

MRI 18/19 95%

Sardanelli F et al. Invest Radiol 2011



Abbreviated Breast Magnetic Resonance Imaging (MRI): First Postcontrast Subtracted Images and Maximum-Intensity Projection—A Novel Approach to Breast Cancer Screening With MRI



Christiane K. Kuhl, Simone Schradang, Kevin Strobel, Hans H. Schild, Ralf-Dieter Hilgers, and Heribert B. Bieling

- prospective observational study in 443 who underwent 606 screening MRIs.
- 17 minutes versus 3 minutes MRI reading protocol
- 11 breast cancers were diagnosed. Median tumor size of 8.4 mm.
- MIP readings were positive in 10 (90.9%) of 11 cancers, with a negative predictive value (NPV) of 99.8% (418 of 419).

Conclusion

An MRI acquisition time of 3 minutes and an expert radiologist MIP image reading time of 3 seconds are sufficient to establish the absence of breast cancer, with an NPV of 99.8%. With a reading time < 30 seconds for the complete AP, diagnostic accuracy was equivalent to that of the FDP and resulted in an additional cancer yield of 18.2 per 1,000.

SCREENING FOR HIGH RISK PATIENTS






Rethinking Breast Cancer Screening: Ultra FAST Breast Magnetic Resonance Imaging

Elizabeth A. Morris, Memorial Sloan Kettering Cancer Center, New York, NY





44 yo

BRCA 1 carrier

G2 IDC



50yo
BRCA carrier
Annual screening



4D-TRAK XD

Field strength	1.5T, 3.0T.
Main applications	Angiography.
Sequence	Dynamic contrast-enhanced MR Angiography.
Maps	MIP's of multiple phases.
Speed	Leverages the efficient dS SENSE parallel imaging technology to provide superior speed performance. ¹ High spatial and temporal resolution, simultaneously.
Image quality	Optimal signal-to-noise due to dStream's digitization at the patient.

¹ Compared to first generation SENSE.

4D Time-Resolved Angiography using Keyhole



fast, dynamic contrast-enhanced MR Angiography method with flexible sampling of both the arterial- and venous phase enabling high spatial and temporal resolution simultaneously




Editorial Musings

Time to enhancement derived from ultrafast breast MRI as a novel parameter to discriminate benign from malignant breast lesions




Roel D. Mus^a, Cristina Borelli^{b,c,*,1}, Peter Bult^d, Elisabeth Weiland^e, Nico Karssemeijer^a, Jelle O. Barentsz^a, Albert Gubern-Mérida^a, Bram Platel^a, Ritse M. Mann^a




TWIST acquisition :102 s.



to compare TTE (time to enhancement) to conventional curve type evaluation as a classifier to discriminate between malignant and benign breast lesions.




4D TRAK



THRIVE




4D TRAK CASE 1




4D TRAK



THRIVE



4D TRAK CASE 1







RESPONSE TO NEO-ADJUVANT CHEMOTHERAPY

Author	Correlation coefficient	P-value
Partridge et al.	0.89	<0.001
Cheung et al.	0.982	<0.001
Martincich et al.	0.72	<0.001
Segara et al.	0.749	<0.0001
Kim et al.	0.645	<0.001
Moon et al.	0.584	NA
Wright et al.	0.49	NA
Park et al.	0.667	NA
Nakahara et al.	0.21	NS
Wang et al.	0.866	<0.01
Dongfeng et al.	0.698	<0.001
Fangberget et al.	0.87	<0.001
Guarneri et al.	0.53	NS
Shin et al. ^a	0.97	NA
Chen et al.	0.30	0.03
Kim et al.	0.619	<0.0001
Shin et al. ^b	0.781	NA


NA not available, NS not significant

M Lobbes et al, Insight Imaging, 2013







- SENSITIVITY 82 % (95% CI: 0.6454 - 0.9302)
- SPECIFICITY 86 % (95% CI: 0.6509 - 0.9709)
- ACCURACY 83 % (95% CI: 0.7120 - 0.9223)
- PPV 90 % (95% CI: 0.7347 - 0.9789)
- NPV 76 % (95% CI: 0.5487 - 0.9064)






Telesca M et al. Accuracy of 3T Magnetic Resonance imaging with a high-relaxivity contrast agent in assessing treatment response in patients undergoing NAC. ECR 2015



“ linguini sign”








Extracapsular rupture












ILC







OCCULT BREAST CANCER















Equivocal findings at mammo/US





Case 1: screening patient





Targeted USS : U1





Subtracted - 8_1: T1 Dyn Gad Table Viewer Anatomical Viewer









Invasive carcinoma type: Ductal with lobular features (E-cadherin positive on core biopsy)
Grade: 2
Focality: unifocal
Invasive tumour measurement: 10mm

CASE 2: screening patient






24/05/2018
15:38:31.812




Mags
Slice 148/230
MR
Max Enhancement
Alexandra Hospital
Sies TR: 2.0 / -1.0
FOV 333 mm
Zoom 160%




Thickness: 75.0 mm
Slab pos: -21.5 mm
FOV 333 mm
Zoom 100%

10:29:59
Scan Nr. 5, 2
T1FFEAV
TR 6ms
Flip Angle 15°
Dt 3:10



Graph Viewer Anatomical Viewer






Second look USS: columnar cell changes with atypia and sclerosing Adenosis. B3.

Im: 0

L 2048
W 2090

R breast WLE : atypical ductal hyperplasia

L breast therapeutic
mammoplasty :
grade 3 infiltrating duct
carcinoma
DCIS at the site of the posterior
wire



CRITICISMS



- **Cost and limited access**
- **Technical** (high-quality MR systems, dedicated breast coils, contrast agents)
- **Interpretation**
- **Clinical** (treatment delay, unnecessary biopsy, etc..)

EVIDENCE-BASED INDICATION??

LONG TERM OUTCOMES??

TAKE HOME POINTS

- 1. Breast MRI has been increasingly used and investigated, and shows a great potential for the future**
- 2. Breast MRI has not only high sensitivity but also good specificity**
- 3. Breast MRI entered the high-risk screening but controversy on indications will continue, especially for the preoperative setting**
- 4. Breast MRI is a valid technique in assessing response to NAC**
- 5. Breast MRI may expand its role from diagnosis to prognosis**



- Increased access to the modality
- implementation of new protocols
- Interaction between clinicians
- High quality research

